KLARIA PHARMA HOLDING AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.294 SEK | +5.38% |
|
+62.88% | -36.36% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Klaria Pharma Holding AB (publ) is a Sweden-based holding company engaged in the biotechnology and medical research industry. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The Company operates Klaria Pharma AB as a wholly owned subsidiary.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.36% | 2.72M | |
| +2.49% | 96.73B | |
| -0.47% | 21.31B | |
| -16.61% | 21.21B | |
| -5.01% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- KLAR Stock
- News Klaria Pharma Holding AB
- Klaria Pharma Files EU Marketing Authorization Application for Migraine Treatment; Shares Up 10%
